These results indicated that FMT could continuously monitor the growth of 22Rv1-iRFP-GFP orthotopic tumors, and that the tk gene driven by the PSA promoter (encapsulated by JCPyV VLP) could inhibit orthotopic prostate cancer growth. This evidence concerns the gene KLK3 and prostate carcinoma.